Please ensure Javascript is enabled for purposes of website accessibility

Alnylam Scores a $2 Billion Investment From Blackstone

By Cory Renauer - Apr 13, 2020 at 3:13PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The multipart deal will, among other things, give the world's largest alternative investment firm a piece of the profits from the biotech's revolutionary new cholesterol drug.

Investors wondering what Blackstone (BX) would do with the gigantic new life sciences fund it was launching got a big piece of the picture Monday. The private-equity firm committed $2 billion to Alnylam (ALNY -1.23%) in return for a slate of commitments that include rights to royalties from Novartis (NVS 0.19%) for sales of inclisiran, a gene-silencing drug widely expected to earn approval soon. 

In January, Blackstone raised a whopping $3.4 billion for its life science fund, which has joined forces with the private equity firm's credit platform to offer Alnylam $1 billion for half of the royalties the biotech company is expected to receive from Novartis for inclisiran. Sales of inclisiran could reach $1.7 billion annually in 2024 if the FDA approves it to lower cholesterol for patients who aren't responding well enough to previously available therapies.

Great big pile of cash.

Image source: Getty images.

In addition, Blackrock will acquire $100 million of Alnylam stock, offer the biotech a secured loan of up to $750 million, and will invest up to $150 million into the development of two more experimental gene-silencing treatments: vutisiran and ALN-AGT.

No new share offerings

Alnylam probably won't need to lean on the secured loan from Blackstone, but shareholders will be glad to know there's little chance the biotech will need to visit the equity tap again. Inclisiran hasn't been approved by the FDA yet, but the company finished 2019 with $1.55 billion in cash on its balance sheet and two marketed products on pharmacy shelves.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Alnylam Pharmaceuticals. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Alnylam Pharmaceuticals, Inc. Stock Quote
Alnylam Pharmaceuticals, Inc.
ALNY
$228.17 (-1.23%) $-2.84
Novartis AG Stock Quote
Novartis AG
NVS
$85.54 (0.19%) $0.16
The Blackstone Group L.P. Stock Quote
The Blackstone Group L.P.
BX

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
403%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.